BCRX

Nasdaq

BIOCRYST PHARMACEUTICALS INC

Latest disclosureSeptember 2, 2026

Insider score Why 0?: 0/ 100
Qualifying buys · 30d: $0

0 purchases · 2 sales

Price by TradingView

Insider transactions 34

Limited filing history

Filters

Last 30 daysNo qualifying insider buying. No qualifying insider sales.

Sale disclosed

Amy E. McKee

Director

Common Stock

Reported value: $100.28K
Reported price: $8.97 / share

Sale disclosed

Alane P. Barnes

Chief Legal Officer

Common Stock

Reported value: $596.25K
Reported price: $9.54 / share

Reporting insider	Security / transaction	Amount / price	Value	Traded / disclosed	Source
Director	Common StockSale	11,180$8.97 / share	$100.28K	May 18Filed May 19 · 1d later	SEC filing
Chief Legal Officer	Common StockSale10b5-1	62,500$9.54 / share	$596.25K	May 13Filed May 15 · 2d later	SEC filing

Congress transactions 2

All Congress filings

Purchase disclosed

BioCryst Pharmaceuticals, Inc. - Common Stock (BCRX) · Stock

The filing reports a purchase for the member.

Gilbert CisnerosReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: July 10, 2026

Purchase disclosed

BioCryst Pharmaceuticals, Inc. - Common Stock (BCRX) · Stock

The filing reports a purchase for the member.

Gilbert CisnerosReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: November 13, 2025

Why this buying score?

No qualifying common-equity purchases

No eligible common-equity purchase is public by this cutoff within 180 transaction-date days. Other instruments, exercises and routine activity do not contribute purchase points.

+0 pts

This score describes qualifying insider purchases at issuer level. Read the methodology

Sources and coverage

Limited filing history · Market-wide discovery does not establish complete company history. View coverage

Source: SEC EDGAR · Form 4
Issuer CIK: 0000882796
Latest public acceptance: Sep 2, 2026, 08:16 PM UTC
Score calculated: Oct 8, 2026, 12:04 AM UTC
Parser: form4-parser-1.5
Classifier: form4-classifier-1.1
Scoring methodology: insider-experimental-1.1
Availability: Public filing time, not trade date

Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.

Insider activity can have many explanations. Signal Strength is not a probability of profit or a recommendation to trade.

Reporting insider

Security / transaction

Amount / price

Value

Traded / disclosed

Source

Director

Common StockSale

11,180$8.97 / share

$100.28K

May 18Filed May 19 · 1d later

SEC filing

Chief Legal Officer

Common StockSale10b5-1

62,500$9.54 / share

$596.25K

May 13Filed May 15 · 2d later

SEC filing

Why this buying score?

No qualifying common-equity purchases

No eligible common-equity purchase is public by this cutoff within 180 transaction-date days. Other instruments, exercises and routine activity do not contribute purchase points.

+0 pts

This score describes qualifying insider purchases at issuer level. Read the methodology

Sources and coverage

Limited filing history · Market-wide discovery does not establish complete company history. View coverage

Source: SEC EDGAR · Form 4
Issuer CIK: 0000882796
Latest public acceptance: Sep 2, 2026, 08:16 PM UTC
Score calculated: Oct 8, 2026, 12:04 AM UTC
Parser: form4-parser-1.5
Classifier: form4-classifier-1.1
Scoring methodology: insider-experimental-1.1
Availability: Public filing time, not trade date

Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.